Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, recently received final approval from the US Food & Drug Administration (USFDA) for Amphotericin B Liposome for Injection, 50 mg.

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), AmBisome Liposome for Injection, 50 mg/vial, of Astellas Pharma US, Inc.

As per the statement, the product is expected to be launched by Q4 FY23. The approved product has an estimated market size of around US$ 145 million for the 12 months ending September 2022, according to IQVIA.

Click for more articles on UDFDA

As per the release:

Amphotericin B Liposome for Injection is indicated as empirical therapy for presumed fungal infection in febrile, neutropenic patients, treatment of cryptococcal meningitis in HIV-infected patients, treatment of patients with Aspergillus species, Candida species

and/or Cryptococcus species infections refractory to amphotericin B deoxycholate,

or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate as well as in the treatment of visceral leishmaniasis.

In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following the initial clearance of parasites.

Other drugs approval by USFDA

USFDA gives approval for Potassium-deficiency drug

USFDA gives final approval for Cyclophosphamide capsules

USFDA gives nod to market this generic Antibiotic Drug

USFDA gives tentative approval for Drospirenone tablets

USFDA approves Ketorolac Tromethamine injection

USFDA gives final approval for Sodium Phenylbutyrate tablets
https://thehealthmaster.com/2022/11/19/usfda-gives-nod-for-amphotericin-b-liposome-injection/